Skip to contentM
Marimed Inc.
M
MRMDMarimed Inc. Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$41.65M$41.65Mderived+7.5% vs Q4 2024 Net Income-$4.63M-$4.63MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Marimed Inc. · CIK 1522767 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$10,502,000−15.6% Operating Incomederived-$4,525,000N/M Operating Cash Flowderived$3,429,000N/M Free Cash Flowderived$3,396,000N/M Margins · derivedGross margin25.2%−6.9 pt vs Q4 2024
Operating margin-10.9%−6.4 pt vs Q4 2024
Net margin-11.1%+10.9 pt vs Q4 2024
ended Dec 31, 2025 · filed Mar 12, 2026 · 71 d after period end